Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Lonza Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: www.lonza.com
Phone: 03 9550 0883

Content from other channels on our network

Growing steaks in space

Frozen food market: what's on trend?

tna Connects: virtual learning hub for food manufacturing

Milk processor pays penalty for breach of Dairy Code

Call for comment on new type of sweetener

ABB to leverage digitalisation in project execution

Schneider Electric launches digital load management system

Novel sensor detects oversized ore

FutureOn secures investment from Bentley

Scientists develop 'mini-brains' to help robots recognise pain

Perkins design packs a punch

Movember to launch prostate cancer 'super network'

COVID-19 vaccine: who's in the running?

The copper touch helps bring safety to surfaces

HIV study set to change international treatment recommendations

Lonza bone marrow and cord blood mononuclear cells

AdipoGen Life Sciences tubulin products for neurodegeneration research

SYnAbs monoclonal antibodies

Merck VirusExpress Lentiviral Production Platform

Content from other channels on our network